EVALUASI PENYEBAB DAN PENATALAKSANAAN TERAPI PADA KASUS KERACUNAN SERTA ANALISIS BIAYA by , Megawati Parmasari, , Prof. Dr. Sugiyanto, SU., Apt.

“…The poisoning victims number that increase annually impelling researches to identify toxic agents that cause poisoning and its association to patientâ��s characteristics. Pharmacoeconomic analysis is needed to determine the association between appropriateness of poisoning management and direct medical cost, as well as length of stay (LOS) as an outcome. …”

Drugs for rare disorders by Cremers, S, Aronson, J

“…They can contribute to the delineation of genetic factors that determine clinical outcomes of pharmacological interventions, develop biomarkers, design and perform clinical trials, assist regulatory decision making, and conduct postmarketing surveillance and pharmacoepidemiological and pharmacoeconomic assessments.…”

Analisis Efektivitas Biaya Terapi Antihipertensi Kombinasi Tetap Di Satu Rumah Sakit Jakarta Selatan by Ani Rahayu, Ahmad Fuad Afdhal, Delina Hasan, Feriadi Suwarna, Okpri Meila

“…The majority of alternative antihypertensive therapies require pharmacoeconomic studies, particularly Cost Effectiveness Analysis, which is useful in balancing patients’ expenditure by determining alternative treatments that represented the most plausible health outcomes with a more reasonable budget. …”
Get full text

Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis by Doddy de Queljoe, Amelia Lorensia, Liana Widharta, Sugiarto Widjaja

“…It is a pharmacist’s duty to ensure therapeutic and pharmaceutical care which is not only safe and effective for the patient but also is cost-effective in order to attain improvement of the patient’s quality of life. Therefore, pharmacoeconomic evaluation especially cost-effectiveness analysis (CEA), which compares costs and consequences of drug therapy, is needed. …”
Get full text

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy] by Andrea Belisari, Daria Bettoni, Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Lorenzo Giovanni Mantovani, Gerardo Miceli Sopo, Marino Nonis

“…It is, therefore important to consider these aspects for the Italian environment and to perform a pharmacoeconomic evaluation to define the efficiency of nintedanib in IPF by means of a Cost-Utility Analysis (CUA). …”
Get full text

Stakeholder views of managed entry agreements: A literature review of national studies by Subramaniam Thanimalai, Wai Yee Choon, Kenneth Kwing-Chin Lee

“…Stakeholders also identified the lack of expertise in assessing the pharmacoeconomic and health outcomes data and challenges in assessing risks up-front due to the complexity of the real-world data. …”
Get full text

CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION by N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich

“…</strong> To study clinical equivalence of two amlodipines under the control of their plasma levels and evaluate their pharmacoeconomical efficacy in patients with arterial hypertension (AH).…”
Get full text

Optimizing economic outcomes in the management of COPD by Roberto Dal Negro

“…At present, more precise indices and more fitting outcomes are continuously sought and found in order to assess more effective strategies for controlling COPD.Keywords: COPD, economic outcomes of COPD, COPD burden, COPD pharmacoeconomics…”
Get full text

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study by Lei Zhang, Huafang Li, Yifeng Shen, Wenjuan Yu, Jingjing Huang, Sidi He

“…The secondary objective includes the long-term efficacy of atypical antipsychotics in these patients, as well as pharmacoeconomic evaluation, population pharmacokinetic studies and pharmacogenomics studies.Methods This study has an observational design. …”
Get full text

Use of ACE-inhibitors in Serbia in 2009 and 2010 by Perić Dajana M., Milijašević Dragana S., Tomić Nataša Z., Knežević Aleksandar D., Bukumirović Nina R., Milijašević Boris Ž.

“…The amount and structure of the utilized ACE-inhibitors in Serbia is different from the amount and structure of the utilized ACE inhibitors in Norway. From pharmacoeconomic point of view, high consumption of expensive ACE-inhibitors (plain and fixed combination with diuretics) in 2009 and 2010 in Serbia resulted in the higher spending of funds.…”
Get full text

COVID-19: economic aspects of influenza vaccine prevention by E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich

“…Scores on the Charlson comorbidity scale were calculated for all individuals. The pharmacoeconomical cost of the patient’s treatment was predicted using the Markov model. …”
Get full text

Impiego degli Inibitori della Pompa protonica (IPP) in Piemonte: indagine sulle abitudini prescrittive dei Medici di Medicina Generale by Adriana Ceci, Paola Baiardi, Simona Ravera, Emilia Chiò, Pellegri Cristiana, Cristina Negrini, Giorgio Capitelli, Renato Cela, Giuliana Corda, Ezio Gaia, Sandro Gozzi, Francesco Marocchino, Eleonora Marrazzo, Andrea Pizzini, Aldo Ravaglia, Franco Saullo, Marcello Tonini

“…Moreover, in order to control PPIs expenditure, pharmacoeconomic methodologies can be applied allowing to identify the most cost - effective active substance and therapeutic scheme, overcoming CUF Notes which consider all PPIs use under the same reimbursement conditions.…”
Get full text

Cost-effectiveness of antihypertensive treatment in Malaysia by Al-Efan, Qais Muhammad Ahmad, M. Ibrahim, M. Izham, Abdul Razak, Tariq, Ayob, Azizi

“…Such results will allow health care professionals and/or decision makers to make better decisions on how to select treatment options for hypertensive patients in Malaysia and how to distribute and allocate scarce health care resources. Pharmacoeconomic evaluations can help in making difficult choices rationally and allocate scarce resources efficiently.…”
Get full text

Analisi dei costi di buprenorfina vs metadone nella terapia dei soggetti con dipendenza da oppiacei by Giorgio L. Colombo, Guido Faillace, Michele Ferdico

“…In this paper we present a pharmacoeconomical comparison between buprenorphine and methadone in the treatment of heroin dependence by the Italian health service, adopting the perspective of the Society. …”
Get full text

A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome by Chow John L, Macario Alex, Dexter Franklin

“…A prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU to asses AQMS or intubation times is impractical because of the highly variable clinical course of patients with ARDS.…”
Get full text

Rivaroxaban in atrial fibrillation by Giorgi MA, Miguel LS

“…In addition, rivaroxaban exhibits good pharmacokinetic and pharmacoeconomic properties. Novel anticoagulants are a viable and commercially available alternative to vitamin K antagonists nowadays for the prevention of thromboembolic complications in atrial fibrillation. …”
Get full text

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment by Al Yami MS, Kurdi S, Abraham I

“…Majed S Al Yami,1,2 Sawsan Kurdi,2,3 Ivo Abraham2,4,5 1Department of Pharmacy Practice, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; 3Department of Pharmacy Practice, University of Dammam, Dammam, Saudi Arabia; 4Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; 5Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA Background: Standard-duration (7&ndash;10 days) thromboprophylaxis with low molecular weight heparin, low dose unfractionated heparin, or fondaparinux in hospitalized medically ill patients is associated with ~50% reduction in venous thromboembolism (VTE) risk. …”
Get full text

Clinical characteristics of patients hospitalized to the Ukrainian expert-consultative center of pulmonary hypertension for adults by I. S. Datsenko, A. V. Kabachna

“…Thus, the results of the study of the clinical characteristics of patients hospitalized at the Ukrainian Expert Advisory Center of Pulmonary Hypertension for Adults, indicate the need to determine the technology of specific therapy of PAH with pharmacoeconomic analysis.…”
Get full text

Analisi di costo efficacia nella terapia della BPCO by Sergio Iannazzo, Lorenzo Pradelli, Roberto W. Dal Negro, Mario Eandi

“…OBJECTIVES: To analyze the economical and clinical impact of this recommendation, the affordability of its widespread application, as well as the relative pharmacoeconomical performance of the available options for severe and very severe COPD in Italy. …”
Get full text

4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary inte... by Scott Mosley, Samantha Yeung, David Shavelle, Leonardo Clavijo, Tien Ng

“…Cost of testing, 30-day hospital readmission, and HRQoL questionnaires will be included for pharmacoeconomic analysis from an institutional perspective. …”
Get full text